glp 1 agonists for type 2 diabetes GLP-1 receptor and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits GLP1 Receptor Agonists vs SGLT2-I

Evidence of oxidative stress in Alzheimers disease brain and antioxidant therapy: lights and shadows

L-carnitine

95% CI, 0.26 to 2.04

Abbreviations ACEI: Angiotensin-converting enzyme inhibitors aHR: Adjusted hazard ratio AMI: Acute myocardial infarction ARB: Angiotensin II receptor blockers BMI: Body mass index CVD: Cardiovascular diseases CVOT: Cardiovascular outcome trial CI: Confidence interval CKD: Chronic kidney disease DM: Diabetes mellitus DPP-4i: Dipeptidyl peptidase-4 inhibitor eGFR: Estimated glomerular filtration rate ESKD: End-stage kidney disease GLP-1 RA: Glucagon-like peptide-1 receptor agonist HbA1c: Glycated hemoglobin HCOs: Healthcare organizations IQR: Interquartile range KTR: Kidney transplant recipient MACE: Major adverse cardiovascular events MAKE: Major kidney event PSM: Propensity score matching PTDM: Post-transplant diabetes mellitus RCTs: Randomized clinical trials SBP: Systolic blood pressure SD: Standard deviation SGLT2i: Sodium-glucose cotransporter 2 inhibitor SU: Sulfonylureas T2DM: Type 2 diabetes mellitus TZD: Thiazolidinediones References Rangaswami J, Mathew RO, Parasuraman R, Tantisattamo E, Lubetzky M, Rao S, Yaqub MS, Birdwell KA, Bennett W, Dalal P, et al

If you do not know which chart matches your vial, you are guessing

Guest, Nanci S